Kiniksa Pharmaceuticals International Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BRXB0C07
USD
43.50
-4.27 (-8.94%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
180.85
156.80
137.78
122.54
112.21
108.63
79.86
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
180.85
156.80
137.78
122.54
112.21
108.63
79.86
Raw Material Cost
83.59
71.03
61.69
66.17
49.50
42.45
31.54
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Selling and Distribution Expenses
49.10
46.86
43.53
40.53
46.40
42.40
38.68
Other Expenses
2.41
1.87
1.93
3.51
2.60
2.39
2.62
Total Expenditure (Excl Depreciation)
156.83
136.64
124.51
141.84
121.87
108.75
96.40
Operating Profit (PBDIT) excl Other Income
24
20.2
13.3
-19.3
-9.7
-0.1
-16.5
Other Income
3.14
2.72
2.29
2.32
2.46
2.42
2.27
Operating Profit (PBDIT)
27.54
23.23
15.91
-16.58
-6.80
2.73
-13.81
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
97.26
85.76
76.09
56.36
62.71
66.18
48.32
Depreciation
0.38
0.36
0.34
0.40
0.40
0.43
0.47
Profit Before Tax
27.16
22.88
15.56
-16.98
-7.20
2.30
-14.28
Tax
8.72
5.04
7.03
-8.09
5.49
6.21
3.43
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
18.43
17.83
8.54
-8.89
-12.69
-3.91
-17.70
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
18.43
17.83
8.54
-8.89
-12.69
-3.91
-17.70
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
18.43
17.83
8.54
-8.89
-12.69
-3.91
-17.70
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
535.38
495.01
457.49
438.44
437.01
435.10
431.89
Earnings per share (EPS)
0.23
0.23
0.11
-0.12
-0.18
-0.06
-0.25
Diluted Earnings per share
0.23
0.23
0.11
-0.12
-0.18
-0.06
-0.25
Operating Profit Margin (Excl OI)
13.28%
12.86%
9.63%
-15.75%
-8.61%
-0.11%
-20.71%
Gross Profit Margin
15.23%
14.82%
11.55%
-13.53%
-6.06%
2.52%
-17.29%
PAT Margin
10.19%
11.37%
6.2%
-7.25%
-11.31%
-3.6%
-22.17%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Sep 2025 is 15.37% vs 13.79% in Jun 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is 3.37% vs 109.41% in Jun 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is 19.02% vs 50.74% in Jun 2025

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

Compare Quarterly Results Of Kiniksa Pharmaceuticals International Plc With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
180.85
0
180.85
Other Operating Income
0.00
0.00
0.00
Total Operating income
180.85
0
180.85
Raw Material Cost
83.59
0
83.59
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
49.10
0
49.10
Other Expenses
2.41
0.00
2.41
Total Expenditure (Excl Depreciation)
156.83
0
156.83
Operating Profit (PBDIT) excl Other Income
24.02
0.00
24.02
Other Income
3.14
0
3.14
Operating Profit (PBDIT)
27.54
0
27.54
Interest
0.00
0
0.00
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
97.26
0
97.26
Depreciation
0.38
0
0.38
Profit Before Tax
27.16
0
27.16
Tax
8.72
0
8.72
Provisions and contingencies
0
0
0.00
Profit After Tax
18.43
0
18.43
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
18.43
0
18.43
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
18.43
0
18.43
Equity Capital
0
0
0.00
Face Value
0.00
0
0.00
Reserves
535.38
0
535.38
Earnings per share (EPS)
0.23
0
0.23
Diluted Earnings per share
0.23
0
0.23
Operating Profit Margin (Excl OI)
13.28%
0%
0.00
13.28%
Gross Profit Margin
15.23%
0%
0.00
15.23%
PAT Margin
10.19%
0%
0.00
10.19%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 18.09 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 15.37% vs 13.79% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 61.23% vs 67.46% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 1.84 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 3.37% vs 109.41% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 244.88% vs 8.63% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2.44 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 19.02% vs 50.74% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 362.37% vs 6.06% in Sep 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 13.28%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024